Highest-materiality recent filing
Apimeds Pharmaceuticals appoints Sungjoon Chae as Co-CEO
Sungjoon Chae appointed Co-CEO effective May 4, 2026, pursuant to a stockholder nomination.
Apimeds settles merger dispute; Lokahi provides $4M working capital; board to transition
Settlement resolves all disputes from Dec 2025 Merger Agreement; Lokahi retains Apitox program assets valued at ~$2.2M.
Apimeds gets NYSE American delisting notice for late 10-K; trading halt continues
Received NYSE American notice on April 17, 2026 for failure to file 2025 10-K on time.
Apimeds expects NYSE notice for late 10-K filing; targets April 30
Filed Form 12b-25 on March 31, 2026 for FY 2025 10-K; will not file within 15-day extension.
Apimeds: Majority stockholder consent to remove directors/officers is null and void
Inscobee Inc. and Apimeds, Inc. attempted written consent to remove directors Kogan, Koo, O’Donnell, Weintraub and officers Menon (CEO) and Frim (CFO).
On March 20, 2026, Inscobee and Apimeds Korea claimed to remove all four directors and CEO/CFO via written consent.
Apimeds US board and CEO ousted; new board approves expansion into Korean cosmetics and photo booth
Majority stockholders removed directors Elona Kogan, Jakap Koo, Carol O’Donnell, Dr. Bennett Weintraub via written consent.
Apimeds Pharmaceuticals to effect 1-for-10 reverse stock split on March 26, 2026
Stockholders approved 1-for-10 reverse stock split via written consent in December 2025.
MindWave posts six-month net loss $6.6M on zero revenue; digital assets $132.3M
Net loss $6.6M for six months ended Sep 30, 2025 vs net income $57.8M in prior year period.
Apimeds Pharmaceuticals removes director Erik Emerson via stockholder vote
Erik Emerson removed from board of directors effective December 30, 2025.
Apimeds corrects Merger Agreement errors: Preferred Stock issuance rises to 90.9% of equity
Corrected Merger Agreement removes Sections 2.05(b)/(d) (director appointment).
Two directors resign from Apimeds Pharmaceuticals board effective December 5, 2025
Dr. Vin Menon and Amir A. Dossal resigned from the Board of Directors on December 5, 2025.
On Dec 1, 2025, Apimeds (APUS) merged with MindWave Innovations, with MindWave surviving as wholly owned subsidiary.
Apimeds boosts CEO salary to $500K and adds 24-month severance with equity vesting
CEO Erik Emerson's annual base salary increased to $500,000, effective Nov 13, 2025.
Apimeds Pharmaceuticals amends bylaws to allow shareholder action by written consent
Board adopted First Amendment to Bylaws on October 15, 2025, effective immediately.
Apimeds appoints Dr. Susan Kramer SVP Development, Brian Peters to lead ai² division
Dr. Susan Kramer appointed SVP of Development; 30+ years experience including 18 at Genentech.
Apimeds Pharmaceuticals appoints Erick J. Frim as CFO, replacing Mark Corrao
Erick J. Frim, 67, appointed CFO effective May 30, 2025, succeeding Mark Corrao.
Apimeds extends maturity of three promissory notes to May 19, 2026
Amended notes from Inscobee ($100k and $150k) and Apimeds Korea ($250k), total $500k principal.
Apimeds Pharmaceuticals US completes $13.5M IPO; starts trading on NYSE American
IPO of 3,375,000 shares at $4.00/share; gross proceeds $13.5M.
Apimeds amends bylaws: reduces quorum, eliminates written consent, raises bar for director removal
Quorum reduced from majority to 33 1/3% of outstanding shares.
On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the " Company "), the board of directors of the Company (the " Board ") appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.
Under the Settlement Agreement, the Inscobee Parties have agreed to secure the resignation or removal of Mr. Koo.
On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.
On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.
Max materiality 1.00 · Median 0.62 · Most common event leadership